5 completed, 2 recruiting. 6 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow LY4064809: new trials by email Literature Review of LY4064809 trials Research Report on LY4064809
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Food Effect on Tersolisib (LY4064809) in Healthy Participants Tersolisib, High-fat Meal, Low-fat Meal - Healthy | Phase 1 | Completed | Eli Lilly and Company | 60 | 2026-07-01 | 2026-10-14 |
| A Study of [14C]-LY4064809 in Healthy Participants LY4064809, [14C]-LY4064809 - Healthy | Phase 1 | Completed | Eli Lilly and Company | 7 | 2026-03-27 | 2026-06-08 |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) LY4064809, Placebo, Ribociclib - Breast Neoplasms, Neoplasm Metastasis | Phase 3 | Recruiting | Eli Lilly and Company | 800 | 2025-12-22 | 2026-10-08 |
| A Study of LY4064809 in Healthy Adult Chinese Participants LY4064809 - Healthy | Phase 1 | Completed | Eli Lilly and Company | 10 | 2025-10-24 | 2026-01-16 |
| A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult Participants LY4064809 - Healthy | Phase 1 | Completed | Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company | 36 | 2025-05-20 | 2025-09-23 |
| A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants [14C]-STX-478 - Healthy | Phase 1 | Completed | Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company | 8 | 2025-03-20 | 2025-05-25 |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors STX-478, Fulvestrant, Ribociclib - Breast Cancer, Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 880 | 2023-04-17 | 2026-07-07 |
Breast Neoplasms (2) · Breast Diseases (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neoplasms by Site (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1)
Eli Lilly and Company (5) · Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company (2)
United States (6) · Belgium (2) · France (2) · Germany (2) · Ireland (2) · Italy (2) · Japan (2) · Singapore (2) · Spain (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · China (1) · Greece (1)
2023 (1), 2025 (1)